Donald Lo, PhD, Director of the National Center for Advancing Translational Sciences (NCATS), discusses NCATS and its mission as an organization.
Dr. Lo notes the primary goal of NCATS is to help organizations navigate what he calls the “Valley of Death” — the journey between developing a drug and getting it approved. This journey has a failure rate of over 90%.
By partnering with organizations, NCATS subsidizes biotech companies with experienced professionals in order to pursue treatment options. As Dr. Lo explains, this is of particular importance for companies developing rare disease treatments as these treatments can take over a decade and trillions of dollars to make available.
To keep up to date on the latest developments in rare diseases, sign up for our weekly newsletter.